Competitive DNA transfection formulation via electroporation for human adipose stem cells and mesenchymal stem cells

Biological Procedures Online

Michael Flanagan¹  Jeffrey M Gimble³  Gang Yu³  Xueqing Xia²  Bruce A Bunnell⁴  Shulin Li⁵ 

[1] Department of Comparative Biomedical Sciences, Louisiana State University, Skip Bertman Drive, Baton Rouge, LA 70803, USA

[2] Department of Pediatrics Research, The University Texas MD Anderson Cancer Center, Graduate School of Biomedical Sciences, 1515 Holcombe, Houston, TX, USA

[3] Pennington Biomedical Research Center, 6400 Perkins Rd., Baton Rouge, LA 70808, USA

[4] Director, Center for Stem Cell Research and Regenerative Medicine, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, USA

[5] Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA

关键词: Cell therapy;    Transfection;    Stem cells;    Formulation;    Electroporation;   

Others  :  793215
DOI  :  10.1186/1480-9222-14-7

 received in 2012-01-30, accepted in 2012-04-18,  发布年份 2012

【 摘 要 】

Background

Adipose stem cells have a strong potential for use in cell-based therapy, but the current nucleofection technique, which relies on unknown buffers, prevents their use.

Results

We developed an optimal nucleofection formulation for human adipose stem cells by using a three-step method that we had developed previously. This method was designed to determine the optimal formulation for nucleofection that was capable of meeting or surpassing the established commercial buffer (Amaxa), in particular for murine adipose stem cells. By using this same buffer, we determined that the same formulation yields optimal transfection efficiency in human mesenchymal stem cells.

Conclusions

Our findings suggest that transfection efficiency in human stem cells can be boosted with proper formulation.

【 授权许可】

   
2012 Flanagan et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Lee ST, Jang JH, Cheong JW, Kim JS, Maemg HY, Hahn JS, Ko YW, Min YH: Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol 2002, 118:1128-1131.
• [2]de Lima Prata K, Delgado Orellana M, Cunha De Santis G, Kashima S, Fontes AM, de Cássia Viu Carrara R, Vianna Bonini Palma P, Neder L, Tadeu Covas D: Effects of high-dose chemotherapy on bone marrow multipotent mesenchymal stromal cells isolated from lymphoma patients. Exp hematol 2010, 38(4):292-300.
• [3]Dupont KM, Sharma K, Stevens HY, Boerckel JD, Garcia AJ, Guldberg RE: Human stem cell delivery for treatment of large segmental bone defects. Proc Natl Acad Sci USA 2010, 107:3305-3310.
• [4]Katz AJ, Llull R, Hedrick MH, Futrell JW: Emerging approaches to the tissue engineering of fat. Clin Plast Surg 1999, 26:587-603. viii
• [5]Gimble J, Guilak F: Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Cytotherapy 2003, 5:362-369.
• [6]Morizono K, De Ugarte DA, Zhu M, Zuk P, Elbarbary A, Ashjian P, Benhaim P, Chen IS, Hedrick MH: Multilineage cells from adipose tissue as gene delivery vehicles. Hum Gene Ther 2003, 14:59-66.
• [7]Gimble JM, Katz AJ, Bunnell BA: Adipose-derived stem cells for regenerative medicine. Circ Res 2007, 100:1249-1260.
• [8]Bunnell BA, Flaat M, Gagliardi C, Patel B, Ripoll C: Adipose-derived stem cells: isolation, expansion and differentiation. Methods 2008, 45:115-120.
• [9]Josiah DT, Zhu D, Dreher F, Olson J, McFadden G, Caldas H: Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther 2010, 18:377-385.
• [10]Flanagan M, Gimble JM, Yu G, Wu X, Xia X, Hu J, Yao S, Li S: Competitive electroporation formulation for cell therapy. Cancer Gene Ther 2011, 18:579-586.
• [11]Aluigi M, Fogli M, Curti A, Isidori A, Gruppioni E, Chiodoni C, Colombo MP, Versura P, D'Errico-Grigioni A, Ferri E, Baccarani M, Lemoli RM: Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells 2006, 24:454-461.
• [12]Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM: Surface protein characterization of human adipose tissue-derived stromal cells. J Cell Physiol 2001, 189:54-63.
• [13]Wang YH, Ho ML, Chang JK, Chu HC, Lai SC, Wang GJ: Microporation is a valuable transfection method for gene expression in human adipose tissue-derived stem cells. Mol Ther 2009, 17:302-308.
• [14]Wolbank S, Peterbauer A, Wassermann E, Hennerbichler S, Voglauer R, van Griensven M, Duba HC, Gabriel C, Redl H: Labelling of human adipose-derived stem cells for non-invasive in vivo cell tracking. Cell Tissue Bank 2007, 8:163-177.
• [15]Zaragosi LE, Billon N, Ailhaud G, Dani C: Nucleofection is a valuable transfection method for transient and stable transgene expression in adipose tissue-derived stem cells. Stem Cells 2007, 25:790-797.
• [16]Kabanov AV, Lemieux P, Vinogradov S, Alakhov V: Pluronic block copolymers: novel functional molecules for gene therapy. Adv Drug Deliv Rev 2002, 54:223-233.
• [17]Mir LM: Nucleic acids electrotransfer-based gene therapy (electrogenetherapy): past, current, and future. Mol Biotechnol 2009, 43:167-176.
• [18]Zaharoff DA, Henshaw JW, Mossop B, Yuan F: Mechanistic analysis of electroporation-induced cellular uptake of macromolecules. Exp Biol Med (Maywood) 2008, 233:94-105.
• [19]Narang AS, Thoma L, Miller DD, Mahato RI: Cationic lipids with increased DNA binding affinity for nonviral gene transfer in dividing and nondividing cells. Bioconjug Chem 2005, 16:156-168.